References
- Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 4 229 234 9673301
- Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002 360 9326 7 22 12114036
- Colhoun HM Betteridge DJ Durrington PN CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004 364 9435 685 696 15325833
- Keech A Colquhoun D Best J LIPID Study Group Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial Diabetes Care 2003 26 10 2713 2721 14514569
- Krobot KJ Wagner A Siebert U Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins Eur J Prev Cardiol 2012 19 1 109 117 21450620
- Chapman MJ Ginsberg HN Amarenco P European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management European Heart J 2011 32 11 1345 1361 21531743
- Solano MP Goldberg RB Lipid management in type 2 diabetes Clin Diabetes 2006 24 1 27 32
- Oh RC Lanier JB Management of hypertriglyceridemia Am Fam Physician 2007 75 9 1365 1371 17508532
- Leiter LA Lundman P da Silva PM Drexel H Jünger C Gitt AK DYSIS investigators Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study Diabet Med 2011 28 11 1343 1351 21679231
- Hamilton SJ Chew GT Davis TM Stuckey BG Watts GF Hypertriglyceridaemia in statin-treated type 2 diabetic patients Practical Diabetes International 2011 28 6 257 260
- Graham I Atar D Borch-Johnsen K European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) European Heart J 2007 28 19 2375 2414 17726041
- Eliasson B Svensson AM Miftaraj M Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus – an observational study from the Swedish National Diabetes Register PLoS One 2011 6 4 e18744 21559521
- Reiner Z Catapano AL European Association for Cardiovascular Prevention and Rehabilitation. ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) European Heart J 2011 32 14 1769 1818 21712404
- Kannel WB Vasan RS Triglycerides as vascular risk factors: new epidemiologic insights Curr Opin Cardiol 2009 24 4 345 350 19424059
- Schaefer EW Leung A Kravarusic J Stone NJ Management of severe hypertriglyceridemia in the hospital: a review J Hosp Med 2012 7 5 431 438 22128096